Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population

Fan, Yi; Wei, Feifei; Lang, Yakun; Wang, Shijun

doi:10.1097/hjh.0000000000000478

Cited by 18 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, several non‐antigout agents have shown an SUA‐lowering effect. In patients with or without hyperuricaemia, SUA reduction was observed with losartan (93.39 μmol/L), atorvastatin (39.62 μmol/L), simvastatin (5.95 μmol/L) and fenofibrate (100.11 μmol/L) . Among these, losartan is considered to increase UA excretion, targeting URAT1 encoded by SLC22A12.…”

Section: Discussionmentioning

confidence: 99%

Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials

Zhao

Tian

et al. 2017

Diabetes Obesity Metabolism

285

218

View full text Add to dashboard Cite

The aim of this study was to describe the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM). PubMed, CENTRAL, EMBASE and ClinicalTrials.gov were searched for randomized controlled trials of SGLT2 inhibitors in patients with T2DM up to May 20, 2017. A total of 62 studies, comprising 34 941 patients, were included. Any of the SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, tofogliflozin, luseogliflozin or ipragliflozin) significantly decreased SUA levels compared with control (total weighted mean difference [WMD] -37.73 μmol/L, 95% CI [-40.51, -34.95]). Treatment with empagliflozin resulted in a superior reduction in SUA (WMD -45.83 μmol/L, 95% CI [-53.03, -38.63]). The effect persisted during long-term treatment. Dapagliflozin decreased SUA in a dose-dependent manner (from 5 to 50 mg, P = .014). In subgroup analyses, greater reductions could be observed during the course of early diabetes and the SUA-lowering effect was abolished in patients with chronic kidney disease (estimated glomerular filtration rate <60 mL/min per 1.73 m ). The effect of SGLT2 inhibitors on SUA reduction suggests that this class of drugs might be beneficial for diabetic patients with hyperuricaemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials

Zhao

Tian

et al. 2017

Diabetes Obesity Metabolism

285

218

View full text Add to dashboard Cite

show abstract

“…In a metaanalysis published by Fan et al [ 31 ] randomized controlled trials regarding losartan treatment for AH patients with HU in China with 2754 patients were analyzed. Losartan significantly reduced serum UA compared with other antihypertensive agents.…”

Section: Discussionmentioning

confidence: 99%

What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?

Nieradko-Iwanicka

2018

Reumatologia

View full text Add to dashboard Cite

Angiotensin receptor blockers or sartans are used to treat arterial hypertension. Hyperuricemia and arterial hypertension often coexist in patients with metabolic syndrome. Also hyperuricemia is correlated with an increased risk of cardiovascular disease and death. There are data suggesting that lowering serum urate may assist in control of arterial hypertension and use of certain drugs for arterial hypertension may reduce the serum uric acid level. The Polish Society of Arterial Hypertension recommends losartan for treatment of arterial hypertension in patients with coexisting hyperuricemia.The aim of the present review was to find evidence supporting the concept of use and explain the role of sartans in treatment of hyperuricemia.Thirty-five original and review articles about hyperuricemia and arterial hypertension focusing on the use of sartans in both these medical conditions were analyzed.In conclusion, sartans should be recommended for treatment of hyperuricemia coexisting with arterial hypertension in patients without bilateral renal artery stenosis and with exclusion of pregnant women.

show abstract

“…Losartan potassium has a uricosuric effect and can decrease cardiovascular events by 13–29% by lowering serum uric acid. [ 102 103 ] Amlodipine is a dihydropyridine calcium antagonist with a uricosuric effect. It is recommended for use in hypertensive patients with ischemic stroke.…”

Section: P Rophylaxis and T Reatment Of mentioning

confidence: 99%

“…For each additional increase of 60 μmol/L in serum uric acid, cardiovascular mortality and ischemic heart disease mortality increase by 26% and 30% in women and by 9% and 17% in men, respectively, and the risk of coronary heart disease increases in women by 48%. [ 101 102 ] HUA is an independent risk factor for all-cause mortality and coronary heart disease mortality in women. The effects of HUA on the development and prognosis of coronary heart disease differ between men and women, possibly because of the effects of estrogen.…”

Section: P Rophylaxis and T Reatment Of mentioning

confidence: 99%

Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases

2017

Chinese Medical Journal

View full text Add to dashboard Cite

Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population

Abstract: There are no significant differences between losartan and other antihypertensive agents in the reduction of blood pressure. However, losartan is superior to other agents in the reduction of serum uric acid levels; it might be a better choice in hypertensive patients with hyperuricaemia.

Cited by 18 publications

References 21 publications

Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials

Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials

What is the role of angiotensin receptor blockers in treatment of hyperuricemia coexisting with arterial hypertension?

Chinese Multidisciplinary Expert Consensus on the Diagnosis and Treatment of Hyperuricemia and Related Diseases

Contact Info

Product

Resources

About